GeneDx reports Q4 adjusted loss $ 17.8M

Reports Q4 revenue $58.1M, consensus $. “Our strong fourth quarter results were a product of our relentless focus on exome and genome revenue growth, uplift from gross margin expansion, and continued efforts to meaningfully reduce our cash burn,” said Katherine Stueland, Chief Executive Officer of GeneDx. “With our focus and disciplined approach to delivering on our goals in 2024, we are confident in our ability to continue to execute and reach profitability in 2025 .”Expanded fourth quarter 2023 adjusted gross margins from continuing operations to 56%;Narrowed fourth quarter 2023 adjusted net los to $17.8M and delivered 51% year-over-year cash burn reduction; Issued guidance to deliver between $220M and $230M in FY 2024 revenue and reiterate path to profitability in 2025nh bn